JB Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.1M Sell
1,201
-18
-1% -$18.2K 0.04% 137
2025
Q4
$1.31M Buy
1,219
+5
+0.4% +$4.78K 0.05% 125
2025
Q3
$926K Buy
1,214
+118
+11% +$87.8K 0.04% 138
2025
Q2
$854K Sell
1,096
-6
-0.5% -$4.66K 0.04% 135
2025
Q1
$910K Sell
1,102
-7
-0.6% -$5.83K 0.05% 122
2024
Q4
$856K Sell
1,109
-28
-2% -$23.2K 0.05% 115
2024
Q3
$1.01M Buy
1,137
+133
+13% +$120K 0.06% 118
2024
Q2
$909K Sell
1,004
-2,866
-74% -$2.29M 0.06% 117
2024
Q1
$3.01M Buy
3,870
+2,904
+301% +$2.07M 0.2% 66
2023
Q4
$563K Buy
966
+31
+3% +$18.1K 0.04% 126
2023
Q3
$502K Buy
935
+106
+13% +$54.6K 0.04% 118
2023
Q2
$389K Buy
829
+59
+8% +$24.7K 0.03% 123
2023
Q1
$265K Buy
770
+69
+10% +$23.3K 0.02% 143
2022
Q4
$257K Sell
701
-12
-2% -$4.25K 0.03% 151
2022
Q3
$231K Sell
713
-677
-49% -$214K 0.03% 146
2022
Q2
$451K Buy
1,390
+526
+61% +$158K 0.05% 171
2022
Q1
$248K Sell
864
-327
-27% -$84.2K 0.02% 215
2021
Q4
$329K Buy
1,191
+186
+19% +$47.2K 0.03% 200
2021
Q3
$232K Buy
+1,005
New +$248K 0.03% 287

Other funds holding LLY

JB Capital's LLY Position: Q1 2026 in Review

JB Capital reduced its Eli Lilly (LLY) stake by 1.5% in Q1 2026, selling an estimated $18.2K and leaving 1,201 shares worth $1.1M. The position accounts for 0.04% of the portfolio, ranked #137.

JB Capital first reported a position in LLY in Q3 2021 and has held it in 19 quarters since. The position peaked at $3.01M in Q1 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • JB Capital held 1,201 shares of Eli Lilly worth $1.1M as of Q1 2026.
  • JB Capital sold 18 Eli Lilly shares in Q1 2026, an estimated $18.2K.
  • Eli Lilly made up 0.04% of JB Capital's portfolio in Q1 2026, its #137 holding.
  • JB Capital first reported a position in Eli Lilly in Q3 2021 and has held it in 19 quarters since.
  • JB Capital's Eli Lilly position peaked at $3.01M in Q1 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on JB Capital's 13F filing for Q1 2026, filed 27 Apr 2026.